Vascodagama Online Journal

“ESR1-mutated Metastatic Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the ESR1-mutated Metastatic Breast Cancer Market.

The ESR1-mutated Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the ESR1-mutated Metastatic Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel ESR1-mutated Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years. 
• ESR1-mutated Metastatic Breast Cancer companies working in the treatment market are Sun Pharma Advanced Research Company Ltd., Eisai Co Ltd, Olema Pharmaceutical, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals/Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Inc., Zenopharm, Arvinas, Roche, Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others, are developing therapies for the ESR1-mutated Metastatic Breast Cancer treatment 

• Emerging ESR1-mutated Metastatic Breast Cancer therapies in the different phases of clinical trials are- SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, Giredestrant (RG6171, GDC-9545), ZN-c5, OP1250, and others are expected to have a significant impact on the ESR1-mutated Metastatic Breast Cancer market in the coming years.   
• On October 21, 2022, Today at the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami, Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing novel therapeutics for the treatment of ESR1-mutated metastatic breast and gynaecological cancers specifically, presented additional findings from its Phase II Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) study.
• On August 17, 2022, Amcenestrant, an experimental oral selective oestrogen receptor degrader (SERD), has had its global clinical development programme stopped by Sanofi.
• In August 2022, Following the conclusion of their current clinical studies, which are closed to accrual in these two programmes, Zentalis announced that they had stopped the clinical development of ZN-c5, their oral SERD, and ZN-e4, their EGFR inhibitor.
•  In August 2022, The FDA gave elacestrant’s NDA for use in patients with advanced or metastatic breast cancer that is oestrogen receptor (ER)-positive/HER2-negative priority review. The regulatory body must make a decision on the application by February 17, 2023, in accordance with the Prescription Drug User Fee Act.
• In August 2022, To treat patients with ER-positive, HER2-metastatic breast cancer, the FDA gave OP-1250 a fast-track designation.
• In April 2022, In its first-quarter results announcement, Roche noted that giredestrant, a newly developed oral selective oestrogen receptor degrader (SERD) class drug, fell short in the Phase II acelERA trial in advanced breast cancer.

ESR1-mutated Metastatic Breast Cancer Overview

Metastatic breast cancer, which begins in breast tissue before spreading to other body areas, is essentially a Stage IV breast cancer. The steroid hormone estradiol is essential for the development of breast cancer, and the majority of human breast cancers begin as estrogen-dependent and ER-positive.

Get a Free Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-pipeline-insight

Emerging ESR1-mutated Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• SCO-120: Sun Pharma Advanced Research Company Ltd.
• H3B-6545: Eisai Co Ltd
• OP1250: Olema Pharmaceutical
• Lasofoxifene: Sermonix Pharmaceuticals
• Camizestrant (AZD9833): AstraZeneca
• Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
• Ibrance (Palbociclib): Pfizer
• Rintodestrant (G1T48): G1 Therapeutics, Inc.
• ZB716: Zenopharm
• ARV-471: Arvinas
• Giredestrant (RG6171, GDC-9545): Roche
• ZN-c5: Zentalis Pharmaceuticals
• OP1250: Olema Pharmaceuticals

ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics Assessment

• ESR1-mutated Metastatic Breast Cancer Assessment by Product Type
• ESR1-mutated Metastatic Breast Cancer By Stage and Product Type
• ESR1-mutated Metastatic Breast Cancer Assessment by Route of Administration
• ESR1-mutated Metastatic Breast Cancer By Stage and Route of Administration
• ESR1-mutated Metastatic Breast Cancer Assessment by Molecule Type
• ESR1-mutated Metastatic Breast Cancer by Stage and Molecule Type

DelveInsight’s ESR1-mutated Metastatic Breast Cancer Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further ESR1-mutated Metastatic Breast Cancer product details are provided in the report. Download the ESR1-mutated Metastatic Breast Cancer pipeline report to learn more about the emerging ESR1-mutated Metastatic Breast Cancer therapies

Some of the key companies in the ESR1-mutated Metastatic Breast Cancer Therapeutics Market include:

Key companies developing therapies for ESR1-mutated Metastatic Breast Cancer are – Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Eisai, Roche, AstraZeneca, Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others.

ESR1-mutated Metastatic Breast Cancer Pipeline Analysis:

The ESR1-mutated Metastatic Breast Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of ESR1-mutated Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESR1-mutated Metastatic Breast Cancer Treatment.
• ESR1-mutated Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ESR1-mutated Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESR1-mutated Metastatic Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about ESR1-mutated Metastatic Breast Cancer drugs and therapies

ESR1-mutated Metastatic Breast Cancer Pipeline Market Drivers

• Rise in global prevalence of ESR1 gene in Metastatic Cancer, increasing research and development activities, technological advancements are some of the important factors that are fueling the ESR1-mutated Metastatic Breast Cancer Market.

ESR1-mutated Metastatic Breast Cancer Pipeline Market Barriers

• However, poor Understanding of the disease and its prognosis, lack of Efficient Diagnostic Tools and other factors are creating obstacles in the ESR1-mutated Metastatic Breast Cancer Market growth.

Scope of ESR1-mutated Metastatic Breast Cancer Pipeline Drug Insight    

• Coverage: Global
• Key ESR1-mutated Metastatic Breast Cancer Companies: Sun Pharma Advanced Research Company Ltd., Eisai Co Ltd, Olema Pharmaceutical, Sermonix Pharmaceuticals, AstraZeneca, Radius Pharmaceuticals/Berlin-Chemie (Menarini Group), Pfizer, G1 Therapeutics, Inc., Zenopharm, Arvinas, Roche, Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others
• Key ESR1-mutated Metastatic Breast Cancer Therapies: SCO-120, H3B-6545, OP1250, Lasofoxifene, Camizestrant (AZD9833), Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), ZB716, ARV-471, Giredestrant (RG6171, GDC-9545), ZN-c5, OP1250, and others
• ESR1-mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-mutated Metastatic Breast Cancer current marketed and ESR1-mutated Metastatic Breast Cancer emerging therapies
• ESR1-mutated Metastatic Breast Cancer Market Dynamics: ESR1-mutated Metastatic Breast Cancer market drivers and ESR1-mutated Metastatic Breast Cancer market barriers 

Request for Sample PDF Report for ESR1-mutated Metastatic Breast Cancer Pipeline Assessment and clinical trials

Table of Contents 

1. ESR1-mutated Metastatic Breast Cancer Report Introduction

2. ESR1-mutated Metastatic Breast Cancer Executive Summary

3. ESR1-mutated Metastatic Breast Cancer Overview

4. ESR1-mutated Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. ESR1-mutated Metastatic Breast Cancer Pipeline Therapeutics

6. ESR1-mutated Metastatic Breast Cancer Late Stage Products (Phase II/III)

7. ESR1-mutated Metastatic Breast Cancer Mid Stage Products (Phase II)

8. ESR1-mutated Metastatic Breast Cancer Early Stage Products (Phase I)

9. ESR1-mutated Metastatic Breast Cancer Preclinical Stage Products

10. ESR1-mutated Metastatic Breast Cancer Therapeutics Assessment

11. ESR1-mutated Metastatic Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. ESR1-mutated Metastatic Breast Cancer Key Companies

14. ESR1-mutated Metastatic Breast Cancer Key Products

15. ESR1-mutated Metastatic Breast Cancer Unmet Needs

16 . ESR1-mutated Metastatic Breast Cancer Market Drivers and Barriers

17. ESR1-mutated Metastatic Breast Cancer Future Perspectives and Conclusion

18. ESR1-mutated Metastatic Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services